Skip to main content

Table 7 CLART, LA, and HC2: sensitivity and specificity for ≥ CIN2 and ≥ CIN3

From: Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study

  CLART LA HC2
Endpoint: ≥CIN2    
Sensitivity (95% CI) 0.93 (0.87-0.97) 0.96 (0.91-0.99) 0.98 (0.94-1.00)
Relative sensitivity vs. LA 0.97 (0.91-1.03) 1.0 (ref) 1.03 (0.98-1.07)
Relative sensitivity vs. HC2 0.94 (0.89-1.00) 0.98 (0.94-1.02) 1.0 (ref)
Specificity 0.30 (0.25-0.36) 0.26 (0.21-0.32) 0.17 (0.12-0.22)
Relative Specificity vs. LA 1.16 (0.88-1.54) 1.0 (ref) 0.64 (0.46-0.90)
Relative Specificity vs. HC2 1.81 (1.30-2.52) 1.56 (1.11-2.19) 1.0 (ref)
Endpoint ≥ CIN3    
Sensitivity (95% CI) 0.93 (0.86-0.98) 0.97 (0.91-0.99) 0.99 (0.94-1.00)
Relative sensitivity vs. LA 0.97 (0.90-1.03) 1.0 (ref) 1.02 (0.98-1.07)
Relative sensitivity vs. HC2 0.94 (0.89-1.00) 0.98 (0.94-1.02) 1.0 (ref)
Specificity 0.28 (0.23-0.33) 0.23 (0.19-0.29) 0.15 (0.11-0.20)
Relative Specificity vs. LA 1.17 (0.89-1.55) 1.0 (ref) 0.64 (0.45-0.90)
Relative Specificity vs. HC2 1.84 (1.32-2.56) 1.57 (1.11-2.21) 1.0 (ref)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us